Lexicon Pharmaceuticals, Inc. (LXRX)

Market Cap	396.10M
Revenue (ttm)	58.43M
Net Income (ttm)	-120.62M
Shares Out	363.40M
EPS (ttm)	-0.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,093,242
Open	1.080
Previous Close	1.100
Day's Range	1.060 - 1.110
52-Week Range	0.284 - 2.175
Beta	1.27
Analysts	Buy
Price Target	3.23 (+196.33%)
Earnings Date	Nov 11, 2025

About LXRX

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates u...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 7, 2000
• Employees: 103
• Stock Exchange: NASDAQ
• Ticker Symbol: LXRX
• Website: https://www.lexpharma.com

Financial Performance

In 2024, Lexicon Pharmaceuticals's revenue was $31.08 million, an increase of 2481.48% compared to the previous year's $1.20 million. Losses were -$200.40 million, 13.1% more than in 2023.

Analyst Summary

According to 5 analysts, the average rating for LXRX stock is "Buy." The 12-month stock price target is $3.23, which is an increase of 196.33% from the latest price.

Price Target

$3.23

(196.33% upside)

Analyst Consensus: Buy